Filing Details
- Accession Number:
- 0001140361-25-005257
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-02-20 16:05:34
- Reporting Period:
- 2025-02-18
- Filing Date:
- 2025-02-20
- Accepted Time:
- 2025-02-20 16:05:34
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 887359 | Vericel Corp | VCEL | Biological Products, (No Disgnostic Substances) (2836) | 943096597 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1916145 | Jonathan Siegal | 64 Sidney Street Cambridge MA 02139 | Principal Accounting Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2025-02-18 | 2,500 | $0.00 | 3,706 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-02-18 | 1,044 | $57.28 | 2,662 | No | 4 | F | Direct | |
| Common Stock | Acquisiton | 2025-02-18 | 420 | $0.00 | 3,082 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-02-18 | 166 | $57.28 | 2,916 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2025-02-19 | 1,710 | $56.72 | 1,206 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | F | Direct | |
| No | 4 | M | Direct | |
| No | 4 | F | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Unit | Acquisiton | 2025-02-18 | 2,500 | $0.00 | 2,500 | $0.00 |
| Common Stock | Restricted Stock Unit | Acquisiton | 2025-02-18 | 420 | $0.00 | 420 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 5,000 | No | 4 | M | Direct | ||
| 420 | No | 4 | M | Direct |
Footnotes
- The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 17, 2023. The remaining RSUs will vest in annual installments on February 17, 2026, and February 17, 2027, respectively.
- These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs.
- The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 18, 2022. The remaining RSUs will vest on February 18, 2026.
- The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2024.
- Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.
- No expiration date for this type of award.
- The Fair Market Value of the vested derivative securities is $57.28 per share.
Billionaire Hedge Funds
